AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive...
NORTH CHICAGO, Ill., May 12, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that 18 abstracts in its gastroenterology and hepatology programs will be presented at Digestive Disease Week® (DDW)...
View ArticleViiV Healthcare launches phase III programme to evaluate a long-acting,...
(Source: GSK - GlaxoSmithKline plc) Issued: London Studies will investigate monthly dosing with injectable cabotegravir and rilpivirine ViiV Healthcare, the global specialist HIV company majority owned...
View ArticleViiV starts PhIII LA injectable treatment regimen (GSK - GlaxoSmithKline plc)
(Source: GSK - GlaxoSmithKline plc) PRESS RELEASE ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen Studies will investigate monthly dosing with...
View ArticleEnanta Announces SVR12 results of 95% from AbbVie’s GIFT-1 Study in...
(Source: Enanta Pharmaceuticals Inc) Sustained virologic response 12 weeks post-treatment (SVR12) of 91 percent was achieved in Japanese patients with genotype 1b (GT1b) hepatitis C virus (HCV)...
View ArticleEuropean Commission Grants Marketing Authorizations for AbbVie's VIEKIRAX®...
(Source: AbbVie Inc) - In Phase 3 clinical trials, VIEKIRAX + EXVIERA cured 95-100 percent of genotype 1 chronic hepatitis C patients, with less than 2 percent of patients experiencing virologic...
View ArticleAbbVie Presents New Data for its Investigational Hepatitis C Treatment in...
(Source: AbbVie Inc) - Primary endpoint of 95 percent and secondary endpoint of 91 percent SVR12 achieved in genotype 1b hepatitis C virus infected Japanese patients without and with compensated...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
NORTH CHICAGO, Ill., Sept. 28, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved...
View ArticleAbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of...
New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin) cured an...
View ArticleAbbVie Receives Health Canada Approval of HOLKIRA™ PAK for the Treatment of...
New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for genotype 1 hepatitis C patients In Phase 3 clinical trials, HOLKIRA PAK (with or without ribavirin) cured an...
View ArticleEnanta Pharmaceuticals Announces Data Presentations on Regimens Containing...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitors Paritaprevir and ABT-493 at The International Liver Congress™ 2015...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
NORTH CHICAGO, Ill., Oct. 1, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that data from its ongoing Phase 1 through Phase 3 hepatitis C clinical development programs will be presented at The...
View ArticleAbbVie Demonstrates Commitment to Continued Research in Hepatitis C with...
(Source: AbbVie Inc) Data from 25 accepted abstracts include results from: -- AbbVie's investigational treatment in liver transplant recipients with recurrent genotype 1 (GT1) chronic hepatitis C virus...
View ArticleAbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) Receives...
(Source: AbbVie Inc) NORTH CHICAGO, Ill., Sept. 28, 2015/PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the Japanese Ministry of Health, Labour and...
View ArticleAbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir...
(Source: AbbVie Inc) Mar 30, 2016 NORTH CHICAGO, Ill., March 30, 2016 /PRNewswire / -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for...
View ArticleAbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C...
NORTH CHICAGO, Ill., June 24, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained...
View ArticleEnanta Announces JAMA Publication of Results from AbbVie’s Study of VIEKIRA...
(Source: Enanta Pharmaceuticals Inc) Enanta Announces JAMA Publication of Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic...
View ArticleAbbVie Announces Real-World Data with VIEKIRAX®...
BARCELONA, Spain, April 15, 2016 /PRNewswire/ -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505...
View ArticleEnanta Pharmaceuticals Announces Preliminary Data from AbbVie’s Phase 3b...
(Source: Enanta Pharmaceuticals Inc) Enanta Pharmaceuticals Announces Preliminary Data from AbbVie's Phase 3b RUBY-I Study in Chronic Hepatitis C Patients with Renal Impairment Presented at The...
View ArticleEnanta Pharmaceuticals Announces Data on Eight-Week Treatment of AbbVie’s...
(Source: Enanta Pharmaceuticals Inc) AbbVie reports 98 percent of previously untreatedgenotype 1b (GT1b) chronic hepatitis C virus (HCV) infected patients without cirrhosis achieved SVRin Phase 3b...
View Article